紫杉醇联合洛铂腹腔化疗治疗晚期卵巢癌恶性腹水疗效观察

Paclitaxel intravenous infusion combined with lobaplatin intraperitoneal chemotherapy for advanced ovarian cancer with malignant ascites

目的观察紫杉醇联合洛铂腹腔灌注化疗治疗晚期卵巢癌恶性腹水的疗效和不良反应。方法收集2010年3月-2012年12月32例晚期卵巢癌患者合并恶性腹水,给予紫杉醇联合洛铂腹腔化疗,紫杉醇135 mg/m2静滴,第1天;洛铂30 mg/m2腹腔灌注,第2天;每4周1疗程。完成2个疗程后评价疗效并观察不良反应。结果全组32例均可评价疗效和不良反应,完全缓解(CR)10例,缓解率31.3%,部分缓解(PR)20例,缓解率为62.5%,总有效率为93.8%。主要不良反应为骨髓抑制,消化道反应轻,未见肝肾功能损害等毒副反应,无治疗相关性死亡。结论紫杉醇联合洛铂腹腔化疗治疗晚期卵巢癌恶性腹水不良反应轻,在短时间内显著控制腹水,改善患者生存质量,值得临床进一步观察和应用。

Objective To investigate efficacy and toxicity of paclitaxel intravenous infusion combined with lobaplatin intraperitoneal chemotherapy for advanced ovarian cancer with malignant ascites. Methods From March 2010 to December 2012, 32 patients with advanced ovarian cancer combined with malignant ascites were enrolled in this study. Paclitaxel was given at a dose of 135mg/m2 ivgtt dl, lobaplatin 30mg/m2 with intraperitoneal chemotherapy d2. Every 4 weeks was a course of treatment. The efficacy and side effects were evaluated after 2 courses of treatment. Results Therapeutic efficacy and adverse reaction were evaluated in all patients,with 10 cases of CR （31.3% ） and 20 cases of PR（62.5% ） The total response rate was 93.8%. The main side effect was myelosuppression. The gastrointestinal reaction was moderate. There was no case of liver or kidney function damage,or treatment-related death. Conclusion The side effects of paclitaxel intravenous infusion combined with lobaplatin intraperitoneal chemotherapy are moderate. This chemotherapy can effectively reduce the malignant ascites within a short period of time and improve life quality of patients. Thus it is worthy of further clinical observation and application.